国家结直肠癌筛查对结直肠癌发病率及晚期结直肠癌的初步影响
本研究纳入2009-2018年荷兰140,649例结直肠癌患者,评估2014年启动的全国性筛查对分期特异性发病率的影响。筛查启动后筛查年龄组内I-III期出现初期高峰后持续下降,II期和IV期发病率降至筛查前水平以下。筛查发现的III期和IV期患者疾病范围更局限、接受根治性治疗比例更高、总生存显著改善。
要点
- 筛查启动后筛查年龄组内I-III期结直肠癌诊断出现初期高峰,随后持续下降
- 筛查发现III期和IV期结直肠癌更多位于左半结肠,原发肿瘤切除率更高
- 筛查发现IV期患者单器官转移更多(74.5% vs 57.0%,P < .001),总生存显著改善
核心结论
- 全国结直肠癌筛查项目实施五年后,观察到II期和IV期结直肠癌发病率下降。
- 筛查发现的III期和IV期结直肠癌患者疾病范围更局限,与临床发现者相比总生存改善。
研究设计与样本
- 纳入2009-2018年诊断为结直肠癌的居民,评估按分期、年份和检测方法(筛查发现 vs 临床发现)的结直肠癌发病率。
- 比较III期和IV期结直肠癌患者按检测方法分组的患者、肿瘤、治疗特征及生存。
- 共纳入136,882例患者的140,649例结直肠癌。
主要发现
- 筛查启动后筛查年龄组内I-III期结直肠癌诊断出现初期高峰,随后持续下降;总结直肠癌发病率仍高于筛查前,但II期和IV期发病率降至筛查前水平以下。
- 筛查发现的III期结直肠癌位于左半结肠者占43.7% vs 临床发现者30.9%;IV期分别为45.1% vs 36.1%。
- 原发肿瘤切除率:III期结肠99.8% vs 99.0%,直肠97.3% vs 89.7%;IV期结肠65.4% vs 56.6%,直肠47.3% vs 33.5%。
- 筛查发现的IV期结直肠癌患者单器官转移更常见(74.5% vs 57.0%;P < .001),接受根治性意图治疗更频繁(结肠41.3% vs 27.4%;直肠33.8% vs 24.6%)。
- 筛查发现结直肠癌患者总生存显著改善(III期:P < .001;IV期:P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Screening for colorectal cancer (CRC) aims to decrease CRC incidence and mortality. Biennial fecal immunochemical test screening started in the Netherlands in 2014 for individuals 55-75 years of age. This study investigated the effect of screening on stage-specific incidence, with focus on stage III and IV CRC. METHODS: Inhabitants diagnosed with CRC in 2009-2018 were included. CRC incidence per stage, year, and detection method (ie, screen-detected vs clinically detected) was evaluated. Patient, tumor, and treatment characteristics, and survival of patients with stage III and IV CRC, were compared according to the detection method. RESULTS: Included were 140,649 CRCs in 136,882 patients. An initial peak of stage I-III CRC diagnoses after initiation of screening was followed by a continuous decrease within screening-eligible ages. Total CRC incidence remained higher than before screening, although stage II and IV CRC incidence decreased below prescreening levels. Screen-detected CRCs were significantly more frequently located in the left-sided colon (stage III; 43.7% vs 30.9%; stage IV: 45.1% vs 36.1%), and the primary tumor resection rate was higher (stage III colon: 99.8% vs 99.0%, rectum: 97.3% vs 89.7%; stage IV colon: 65.4% vs 56.6%, rectum: 47.3% vs 33.5%). Patients with screen-detected stage IV CRC had significantly more often single-organ metastases (74.5% vs 57.0%; P < .001) and more frequently received treatment with curative intent (colon: 41.3% vs 27.4%; rectum: 33.8% vs 24.6%). Overall survival significantly improved for patients with screen-detected CRCs (stage III: P < .001; stage IV: P < .001). CONCLUSIONS: Five years after the start of a nationwide CRC screening program, a decrease in stage II and IV CRC incidence was observed. Patients with screen-detected stage III and stage IV CRC had less extensive disease and improved survival compared with those with clinically detected CRC.
引用
- Krul MF, Elferink MAG, Kok NFM, et al. Initial Impact of National CRC Screening on Incidence and Advanced Colorectal Cancer. Clin Gastroenterol Hepatol. 2022. PMID: 36116753. doi:10.1016/j.cgh.2022.08.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。